{{Rsnum
|rsid=12901682
|Gene=PSMA4
|Chromosome=15
|position=78540881
|Orientation=plus
|GMAF=0.08586
|Gene_s=PSMA4
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.0 | 0.9 | 99.1
| HCB | 0.0 | 28.9 | 71.1
| JPT | 0.0 | 17.9 | 82.1
| YRI | 2.7 | 31.3 | 66.0
| ASW | 3.5 | 24.6 | 71.9
| CHB | 0.0 | 28.9 | 71.1
| CHD | 0.9 | 23.9 | 75.2
| GIH | 0.0 | 4.0 | 96.0
| LWK | 4.6 | 37.6 | 57.8
| MEX | 0.0 | 1.7 | 98.3
| MKK | 8.3 | 37.2 | 54.5
| TSI | 0.0 | 2.9 | 97.1
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22491018
|Trait=None
|Title=Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|RiskAllele=
|Pval=4E-8
|OR=135.0200
|ORtxt=None
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}